1. Home
  2. PODD vs GKOS Comparison

PODD vs GKOS Comparison

Compare PODD & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insulet Corporation

PODD

Insulet Corporation

SELL

Current Price

$145.42

Market Cap

10.2B

Sector

Health Care

ML Signal

SELL

Logo Glaukos Corporation

GKOS

Glaukos Corporation

SELL

Current Price

$242.60

Market Cap

9.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PODD
GKOS
Founded
2000
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
9.7B
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
PODD
GKOS
Price
$145.42
$242.60
Analyst Decision
Buy
Strong Buy
Analyst Count
26
13
Target Price
$178.57
★ $242.46
AVG Volume (30 Days)
1.2M
★ 1.5M
Earning Date
11-04-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 4.69
N/A
Revenue
★ $2,708,100,000.00
$507,442,000.00
Revenue This Year
$22.02
$53.82
Revenue Next Year
$11.71
$28.60
P/E Ratio
$32.65
★ N/A
Revenue Growth
30.73
★ 32.33
52 Week Low
$126.40
$87.32
52 Week High
$354.88
$255.19

Technical Indicators

Market Signals
Indicator
PODD
GKOS
Relative Strength Index (RSI) 47.66 66.85
Support Level $141.26 $143.30
Resistance Level $153.33 $255.19
Average True Range (ATR) 7.29 14.15
MACD -0.83 1.46
Stochastic Oscillator 9.08 85.89

Price Performance

Historical Comparison
PODD
GKOS

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: